Targeting ␣7 neuronal acetylcholine receptors (nAChRs) with selective agonists and positive allosteric modulators (PAMs) is considered a therapeutic approach for managing cognitive deficits in schizophrenia and Alzheimer's disease. In this study, we describe a novel type II ␣7 PAM, 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744), that exhibits a unique pharmacological profile. In oocytes expressing ␣7 nAChRs, A-867744 potentiated acetylcholine (ACh)-evoked currents, with an EC 50 value of ϳ1 M. At highest concentrations of A-867744 tested, ACh-evoked currents were essentially nondecaying. At lower concentrations, no evidence of a distinct secondary component was evident in contrast to 4-naphthalen-1-yl-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonic acid amide (TQS), another type II ␣7 PAM. In the presence of A-867744, ACh concentration responses were potentiated by increases in potency, Hill slope, and maximal efficacy. When examined in rat hippocampus CA1 stratum radiatum interneurons or dentate gyrus granule cells, A-867744 (10 M) increased choline-evoked ␣7 currents and recovery from inhibition/desensitization, and enhanced spontaneous inhibitory postsynaptic current activity. A-867744, like other ␣7 PAMs tested [1-(5-chloro-2-hydroxyphenyl)-3-(2-chloro-5-trifluoromethyl-phenyl)urea (NS1738), TQS, and 1-(5-chloro-2,4-dimethoxy-phenyl)-3-(5-methyl-isoxazol-3-yl)-urea (PNU-120596)], did not displace the binding of [ 3 H]methyllycaconitine to rat cortex ␣7* nAChRs. However, unlike these PAMs, A-867744 displaced the binding of the agonist 3 H]A-585539 in an ␣7/5-hydroxytryptamine 3 (␣7/5-HT 3 ) chimera, suggesting an interaction distinct from the ␣7 N terminus or M2-3 loop. In addition, A-867744 failed to potentiate responses mediated by 5-HT 3〈 or ␣3␤4 and ␣4␤2 nAChRs. In summary, this study identifies a novel and selective ␣7 PAM showing activity at recombinant and native ␣7 nAChRs exhibiting a unique pharmacological interaction with the receptor.
eromeric ␣/␤ subunit combinations. Currently, 12 neuronal nicotinic subunits have been identified (␣2-␣10; ␤2-␤4) (Paterson and Nordberg, 2000; Gotti et al., 2006) . One subtype abundantly expressed in the central nervous system, including in regions involved in learning and memory (hippocampus and cerebral cortex), is the homomeric ␣7 subunit (Rubboli et al., 1994; Wevers et al., 1994) . Homomeric ␣7 nAChRs, when expressed in heterologous expression systems, activate and desensitize rapidly, and they exhibit relatively higher calcium permeability compared with other nAChR combinations (Sands et al., 1993; Dajas-Bailador and Wonnacott, 2004) . This increased Ca 2ϩ permeability is thought to stimulate downstream events, including extracellular signal-regulated kinase and cAMP response elementbinding protein pathways involved in learning and cognition (Sweatt, 2004; Bitner et al., 2007) . In addition, activation of ␣7 nAChRs contributes to neuronal excitability (Frazier et al., 1998) , modulates the release of excitatory and inhibitory neurotransmitters (Alkondon et al., 2000) , exhibits neuroprotective effects in experimental in vitro models of cellular damage (Levin and Rezvani, 2002) , and shows procognitive effects in in vivo animals models of learning and memory (Cincotta et al., 2008) .
Activation or enhancement of ␣7 nAChR function can occur via either direct agonist activation of the orthosteric site or via positive allosteric modulation. The recent focus on the latter mechanism has led to the identification of structurally diverse positive allosteric modulators (PAMs), including SB-206553 (Dunlop et al., 2009 ), PNU-120596 (Hurst et al., 2005) , TQS , CCMI (also referred as compound 6/Q or XY4083) (Ng et al., 2007) , and NS1738 (Timmermann et al., 2007) . In addition, genistein , galantamine (Samochocki et al., 2003) , bovine serum albumin (Conroy et al., 2003) , SLURP-1 (Chimienti et al., 2003) , an acetylcholinesterase-derived peptide (Zbarsky et al., 2004) , and (2-amino-5-keto)thiazole compounds (Broad et al., 2006 ) also function as PAMs. Based on biophysical properties at least two different profiles of ␣7 PAMs are distinguished: type I-exemplified by 5-HI and genisteinpredominantly increasing peak current amplitude response, and type II-represented by PNU-120596 and TQS-affecting both peak current response and current decay profile (Bertrand and Gopalakrishnan, 2007; Grønlien et al., 2007) . Both type I and II PAMs have been shown to exhibit efficacy in vivo behavioral models. For example, PNU-120596 reversed amphetamine-induced gating deficits in rats, and CCMI improved gating deficits in DBA/2 mice (Hurst et al., 2005; Ng et al., 2007) . These observations show that ␣7 PAMs, belonging to both types, are effective in certain preclinical in vivo models. The differential spectrum of behavioral efficacy relevant to cognitive deficits in Alzheimer's disease and schizophrenia remains to be fully elucidated.
The mechanisms or sites by which PAMs interact with ␣7 nAChRs to enhance the receptor function are incompletely understood. Emerging structure-function studies using chimeric and single amino acid point mutation approaches have suggested distinct regions responsible for the PAM effects of NS1738 and PNU-120596, respectively, in the N terminus and transmembrane domains Young et al., 2008) . Given the structural diversity of ␣7 PAM chemotypes, it is likely that there are multiple allosteric sites on the receptor. Thus, the ␣7 PAM interaction with the nAChRs may be similar to PAM binding to GABA A receptors. At the GABA A receptors, three different allosteric sites have been proposed: 1) within the ion channel domain transmembrane 2, near the extracellular end; 2) in the proximity of the agonist binding sites; and 3) in the linker region stretching from the agonist site loop C to the top of the transmembrane 1 region (Olsen et al., 2004) .
In this study, we describe A-867744, as a novel type II PAM. We demonstrate that this compound selectively potentiates ␣7 but not ␣4␤2, ␣3␤4, or 5-HT 3A receptors and that it displays unique pharmacology based on radioligand and functional studies distinguishing this compound from other known ␣7 PAMs. Briggs et al., 2008) . In brief, three to four lobes from ovaries of female adult X. laevis frogs were removed, manually defolliculated, and treated with collagenase type 1A (2 mg/ml; Sigma-Aldrich) prepared in low-Ca 2ϩ Barth's solution [90 mM NaCl, 1.0 mM KCl, 0.66 mM NaNO 3 , 2.4 mM NaHCO 3 , 10 mM HEPES, 2.5 mM sodium pyruvate, 0.82 mM MgCl 2 , and 0.5% (v/v) penicillin-streptomycin solution purchased from Sigma-Aldrich, pH 7.55] for 1.5 to 2 h at ϳ18°C under constant agitation to obtain isolated oocytes. The oocytes were injected with ϳ20 to 25 ng of human or rat ␣7 nAChR cRNA, or ϳ1 to 5 ng of human 5-HT 3A cRNA, kept at 18°C in a humidified incubator in modified Barth's solution [90 mM NaCl, 1.0 mM KCl, 0.66 mM NaNO 3 , 2.4 mM NaHCO 3 , 10 mM HEPES, 2.5 mM sodium pyruvate, 0.74 mM CaCl 2 , 0.82 mM MgCl 2 , 0.5% (v/v) penicillin-streptomycin solution, pH 7.55] and used 2 to 7 days after injection. Responses were measured by two-electrode voltage-clamp technique using Parallel Oocyte Electrophysiology Test station (Trumbull et al., 2003) . During recordings, the oocytes were bathed in Ba 2ϩ -OR2 solution (90 mM NaCl, 2.5 mM KCl, 2.5 mM BaCl 2 , 1.0 mM MgCl 2 , 5.0 mM HEPES, and 0.0005 mM atropine, pH 7.4) and held at Ϫ60 mV at room temperature (ϳ20°C). Agonists were applied to recording chambers at ϳ6 ml/s as indicated. Modulator test compounds were applied for a minimum of 60 s before agonist application, allowing for sufficient preincubation unless otherwise stated. Agonist application after preincubation with modulator was always done in the presence of the test modulator.
Materials and Methods

Materials
Calcium and FMP Imaging. Functional nAChR activities were assessed in HEK-293 cells expressing human ␣4␤2 or ␣3␤4 subunits and in IMR-32 cells by measuring intracellular calcium changes using Fluo-4 acetoxymethyl ester or no-wash calcium dye (Applied Biosystems/MDS Analytical Technologies/Molecular Devices, Sunnyvale, CA or Invitrogen, Carlsbad, CA) and the fluorometric imaging plate reader (FLIPR) system (Applied Biosystems/MDS Analytical Technologies/Molecular Devices) as described previously Briggs et al., 2008; Gopalakrishnan et al., 2008; Faghih et al., 2009) . The responses in HEK-293 cells expressing ␣7/5-HT 3 chimera were determined using FMP dye (Molecular Devices). In brief, cells were plated at densities of 25,000 to 100,000 cells/well in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and appropriate antibiotic selection (HEK-293-derived cell lines) or minimum essential media supplemented with 10% fetal bovine serum and 1 mM sodium pyruvate, 1% nonessential amino acids, and 1% antibiotic-antimycotic solution (IMR-32 cells) in 96-well clear-bottomed black walled plates precoated with poly-D-lysine and allowed to incubate for 24 to 48 h at 37°C in 5% CO 2 in a humidified environment. After aspirating the media, cells were incubated for ϳ45 to 60 min with Fluo-4 acetoxymethyl ester, no-wash calcium dye, or FMP indicator dye in the dark at room temperature. Calcium dyes were dissolved in Nmethyl-D-glucamine/Ringer's buffer (140 mM N-methyl-D-glucamine, 5 mM KCl, 1 mM MgCl 2 , 10 mM HEPES, and 10 mM CaCl 2 , pH 7.4), whereas FMP dye was dissolved in Ca 2ϩ -and Mg 2ϩ -free phosphate-buffered saline supplemented with 0.1 mM CaCl 2 , 0.1 mM MgCl 2 , and 10 mM HEPES. When required after dye loading, cells were gently washed with the same buffer, removing extracellular dye and leaving ϳ100 l/well after the final wash. The protocol used in studies involving HEK-293-derived cell lines was as follows. Cells were placed in the FLIPR chamber where 50 l of 3ϫ stock concentration of test modulators or buffer prepared in the loading buffer was applied in the first addition for 5 min. In the second addition also for 5 min, 50 l of 4ϫ stock concentrations of agonist (nicotine or PNU-282987) or buffer was added. In IMR-32 cells, double addition protocol was also used. To determine the concentration responses of A-867744, various concentrations of A-867744 were given in the first addition followed by 1 M NS6784 in the second application. In another set of experiments described in Fig. 3 (reactivation by A-867744), NS6784 (1 M) was applied first, followed by MLA (100 or 300 nM) or blank, and last by A-867744 (10 M). All experiments were carried out at room temperature (ϳ20 -22°C).
Whole-Cell Patch-Clamp Recordings in Brain Slices. Hippocampal brain slices were prepared from male Sprague-Dawley rats, fully anesthetized with Ultane (sevoflurane) or with CO 2 gas, sacrificed by decapitation. Brain was rapidly removed and placed into ice-cold either high-Mg 2ϩ artificial cerebral spinal fluid (ACSF: 130 mM NaCl, 2.8 mM KCl, 11.3 mM MgCl 2 , 2.5 mM CaCl 2 , 1.25 mM NaH 2 PO 4 , 10 mM dextrose, and 26 mM NaHCO 3 gassed continuously with 95% O 2 , 5% CO 2 , pH 7.3-7.4 at ambient temperature) or regular Mg 2ϩ ACSF (1 mM MgCl 2 used instead of 11.3 mM). Hippocampal brain slices (250 -400 m in thickness, coronal or 30°p arahorizontal) were prepared using standard procedures and cut at 1 to 3°C using a Vibratome slicer with temperature-controlled oxygenated ACSF bath. Slices were preincubated at 32°C for at least 1 h before use. For each experiment, one slice was selected, placed in a chamber perfused with ACSF at ambient temperature (ϳ22°C), and visualized using an E600FN microscope (Nikon, Tokyo, Japan) with infrared differential interference contrast optics. Whole-cell patchclamp recordings were obtained from either hippocampus CA1 interneurons (stratum radiatum) to access fast somatic ␣7 currents or from hilar dentate gyrus granule cells to measure spontaneous inhibitory postsynaptic currents (IPSCs). Borosilicate glass capillary pipettes were filled with internal solution containing 10 mM CsCl, 0.5 mM CaCl 2 , 1 mM MgCl 2 , 5 mM EGTA, 10 mM HEPES, 2 mM Mg-ATP, 0.3 mM Na-GTP, and 135 mM methanesulfonic acid, adjusted to pH 7.3 with CsOH. Whole-cell recording was established, and neuronal activity was validated using voltage steps to activate characteristic sodium currents. IPSCs, presumably mediated by GABA A transmission, were recorded at 0 mV so that inward cationic currents (e.g., glutamatergic ␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid excitatory postsynaptic currents) would be minimized and anionic currents (GABA A IPSCs) would be outward. IPSCs occurring spontaneously during 5-min epochs were recorded using a MultiClamp 700A amplifier, Digidata 1322A converter, and pClamp 9 software (Axon Instruments, Foster City, CA). When recordings from CA1 interneurons were made, cells were held at Ϫ80 mV in the presence of TTX (0.5 M), APV (20 -50 M), CNQX (20 -50 M), picrotoxin (50 M), and atropine (0.5 M) added to the perfusing bath ACSF to minimize the contribution of neuronally mediated glutamatergic, GABAergic, and muscarinic activities. In the presence of the blockers, ␣7 agonist puffs-10 mM choline or 3 mM ACh in application pipette-were made using a Picospritzer II apparatus (General Valve, Fairfield, NJ) for 5-to 50-ms duration and 10 to 30 psi pressure setting. Puff pipettes were positioned 5 to 20 m away from recording cells. The exact concentration of compound reaching the cells to evoke ␣7 currents cannot be precisely determined, but it would be expected to be considerably lower than in the puff pipette. In dentate gyrus experiments, compounds were applied by bath perfusion (1.8 ml/min flow rate; 600-l chamber). Data were stored in a PC and analyzed using pClamp 9 or MiniAnalysis 6.0.3 software (Synaptsoft, Decatur, GA) as appropriate.
Whole-Cell Patch-Clamp Recordings in HEK-293 Cells Expressing ␣7/5-HT 3 Chimera. Standard whole-cell patch-clamp technique was used to record from HEK-293 cells stably expressing chimeric ␣7/5-HT 3 receptors (i.e., chimera 2 in Bertrand et al., 2008) . Cells were plated 48 to 96 h on round poly-D-lysine-precoated glass coverslips before recordings. Experiments were done using pClamp 8.0 or 9.0 (Applied Biosystems/MDS Analytical Technologies/Axon Instruments) installed on a Dell Pentium III computer connected to an Axon 200B amplifier (Applied Biosystems/MDS Analytical Technologies/Axon Instruments, Sunnyvale, CA). Changes in test solution conditions were obtained using a pulled theta tube controlled by Perfusion Fast-Step system (Warner Instruments, Hamden, CT). The pipette solution contained 120 mM KCl, 30 mM NaCl, 2 mM MgCl 2 , 5 mM EGTA, and 10 mM HEPES, pH 7.2 to 7.3. The bath solution contained 140 mM NaCl, 5 mM KCl, 0.1 mM CalCl 2 , 0.1 mM MgCl 2 ,10 mM HEPES, and 0.5 M atropine. Cells were held at Ϫ80 mV unless specified otherwise.
Radioligand Binding Experiments. Experiments were carried out as described previously . Membrane homogenates were prepared from rat cortex and HEK-293 cells stably expressing chimera (i.e., chimera 2 in Bertrand et al., 2008 Data Analysis. In two-electrode voltage-clamp studies, responses were quantified by measuring peak current amplitude. Peak current responses were expressed as percentage response to 100 M ACh (␣7 currents) or 2 to 3 M 5-HT (5-HT 3A currents) in the presence of varying test modulator concentration responses, or to 1 mM ACh (without PAM) in agonist concentration responses (␣7 oocytes). In Ca 2ϩ imaging or FMP studies, raw fluorescence responses were corrected by subtracting fluorescence values from wells with buffer only added. Peak fluorescent responses were determined over the range of drug exposure using FLIPR software and expressed as a percentage of the reference peak response for 3 to 10 M nicotine (␣4␤2 and ␣3␤4) or 25 nM PNU-282987 (chimera studies) to determine the effects of A-867744. In FMP imaging studies, concentration-response experiments to PNU-292987 were normalized to the maximal control agonist response. Whole-cell patch-clamp responses determined in hippocampus brain slice were normalized to the choline-evoked responses obtained before the addition of A-867744. Radioligand binding K i constants were calculated as described previously ( jpet.aspetjournals.org prepared using Prism (GraphPad Software Inc., San Diego, CA). Data are reported as means with 95% confidence intervals or S.E.M.), n is the number of independent determinations made, and p Ͻ 0.05 was considered statistically significant.
Results
Potentiation of Recombinant Human ␣7 Currents.
A-867744 is a representative and optimized compound from a series of pyrrole analogs functioning as positive allosteric modulators of ␣7 nAChRs (Faghih et al., 2009) . In initial experiments, the effect of A-867744 was examined as an agonist at human ␣7 nAChRs. This compound up to the highest concentration tested of 30 M did not evoke any ␣7 current. Higher concentrations of A-867744 could not be tested due to solubility limitation. When A-867744 was preincubated and ␣7 currents evoked by constant 100 M ACh, concentration-dependent potentiation was noted, with a potency (EC 50 value) of ϳ1 M and maximal efficacy of ϳ730% or 7.3-fold (Figs. 1b and 2a; Table 1 ). As shown in Table 1 , the responses at rat ␣7 nAChRs expressed in X. laevis oocytes were comparable with those identified at human ␣7 nAChRs, illustrating no interspecies differences in the ability of A-867744 to function as an ␣7 PAM. Figure 1b illustrates that A-867744 not only had a strong effect on the peak current response but also affected the decay of the current response that seemed concentration-dependent. In the presence of highest concentration tested (e.g., 3 M A-867744), ACh-evoked currents were essentially nondecaying. Figure  1c depicts representative current responses obtained for another ␣7 PAM, TQS, whose properties were described in detail recently . Although at the higher concentrations tested, both compounds produced similar effects. At lower concentrations, there was a qualitative difference. TQS, but not A-867744, was able to evoke a secondary component with onset distinct from that of the initial current component. This suggests that the underlying mechanisms responsible for modulation by these two PAMs are probably different.
Next, we examined antagonist sensitivity of the current responses to MLA, an ␣7 nAChR antagonist. As shown by Fig. 1d , pretreatment with MLA abolished A-867744 potentiated ACh-evoked current responses. This supports interaction of A-867744 with ␣7 nAChRs.
We have further determined the effect of A-867744 on ACh concentration responses. As shown in Fig. 2b , in the presence of A-867744 (tested at nearly fully efficacious PAM concentration of 5 M), ACh responses were potentiated as reflected by increases in potency (from ϳ150 to 40 M), maximal efficacy (from ϳ110 to 500%), and Hill slope values (ϳ1.5 to 3.5) (Fig. 2b) .
Reactivation of Desensitized ␣7 nAChRs by A-867744. Previously, we and others have shown that type II PAMs, specifically TQS and PNU-120596, were able to reactivate desensitized ␣7 currents (Hurst et al., 2005; Grønlien et al., 2007) . In this study, we examined whether A-867744 exhibits a similar effect. ␣7 nAChR currents were evoked and desensitized by continued presence of ACh, and A-867744 was applied in the presence of ACh (Fig. 1e) . As shown, A-867744 was able to reactivate the desensitized currents, showing a nondecaying steady-state nature. When normalized to 1 mM ACh (without A-867744), the maximal A-867744 reactivated currents were 29.3 Ϯ 11.3% (n ϭ 4) and 59.5 Ϯ 2.0% (n ϭ 5) for 3 and 10 M A-867744 at the indicated concentrations was preapplied and in its presence with ACh was applied as shown. c, effects of another ␣7 PAM, TQS, on ACh-evoked human ␣7 currents. TQS was preapplied at the indicated concentrations and in the continued presence of PAM, ACh was added. Please note that the potentiating effects of A-867744 and TQS at the highest concentrations tested are similar in that both increased peak current amplitude and caused nondecaying current profile. In contrast, at lower concentrations examined (e.g., 1 M for TQS and 100 or 300 nM for A-867744), there is a qualitative difference. TQS, but not A-867744, evoked a distinct secondary component (i.e., the second hump). A-867744 concentration-dependently reduced the ␣7 current decay. jpet.aspetjournals.org PAM, respectively. We also investigated the reactivation of desensitized ␣7 nAChRs by A-867744 in IMR-32 cells using Ca 2ϩ imaging. As shown in Table 1 and Fig. 3 , the addition of a selective ␣7 agonist (NS6784) in the presence of A-867744 evoked Ca 2ϩ transients; in comparison, the application of either A-867744 or ␣7 agonist (NS6784) alone had no effect on basal Ca 2ϩ . When the order was such, the agonist was given first at high concentrations, sufficient to desensitize the ␣7 nAChRs, followed by A-867744, Ca 2ϩ transients were evoked. These A-867744-evoked responses were attenuated or reduced in the presence of 100 and 300 nM MLA by 62 Ϯ 10% (n ϭ 10; p Ͻ 0.001) and 90 Ϯ 10% (n ϭ 4; p Ͻ 0.01), respectively (Fig. 3) , illustrating their dependence on the ␣7 nAChRs.
Selectivity of A-867744. As summarized in Table 1 and Fig. 2a , A-867744 potentiated responses mediated by ␣7 nAChRs, with an EC 50 value of ϳ1 to 2 M as determined by electrophysiology and using Ca 2ϩ imaging in IMR-32 cells endogenously expressing human ␣7 nAChRs. To determine whether A-867744 exhibits selectivity at ␣7 nAChRs, the effects of this compound were examined at two separate nAChR subtypes (human ␣4␤2 and ␣3␤4) and at human 5-HT 3A . A-867744 did not activate directly as an agonist either ␣4␤2 or ␣3␤4 receptor-mediated responses up to the maximal concentration tested of 30 M. In the presence of A-867744, the submaximal nicotine-evoked responses were not enhanced but rather inhibited. The IC 50 value and max- Fig. 1b . Each individual data point is n ϭ 2 to 4; see Table 1 imal inhibition values were ϳ6 M and 96% and 20 M and 64% at ␣4␤2 or ␣3␤4 receptors, respectively ( Fig. 4 ; Table 1 ). These experiments illustrate that A-867744 is probably either a noncompetitive antagonist or negative allosteric modulator. Experiments were also carried out on human 5-HT 3A currents expressed in X. laevis oocytes. A-867744 did not activate any 5-HT 3 current up to the maximal concentration tested of 30 M. In the presence of A-867744 (0.1-30 M), the responses to submaximal 5-HT (2-3 M) were unaffected illustrating lack of modulator activity at this receptor (Fig. 4) . Lack of Potentiation of ␣7/5-HT 3 Chimera Responses by A-867744 . Chimeric ␣7/5-HT 3 receptors offer a unique opportunity to potentially identify domains of the ␣7 nAChR that influence allosteric modulator properties. We used a chimera derived from human ␣7 (N terminus and M2-3 loop) fused with human 5-HT 3A receptor (rest), as described previously , and we expressed the chimeric receptor stably in HEK-293 cells. Both ACh (Fig. 5a) and choline were able to evoke the chimeric currents. When normalized to 3 mM ACh (100%), the addition of 3 mM choline and 30 M ACh produced responses of 74 Ϯ 5% (n ϭ 4) and 46 Ϯ 6% (n ϭ 5), respectively. Consequently, the submaximal concentration of 30 M ACh was used to investigate the effect of A-867744. A-867744 at 10 M did not evoke any current, when added directed, and it failed to potentiate the chimeric currents evoked by 30 M ACh. In fact, a modest degree of inhibition (ϳ50%) was noted (Fig. 5,  a and b) . The effect of A-867744 was not easily reversible.
Effects to A-867744 were also examined by measuring fluorescence changes in membrane potential (FMP dye imaging) in HEK-293 cells expressing chimeric ␣7/5-HT 3A receptors evoked by the ␣7 agonist PNU-282987. As depicted in Fig. 5d , PNU-282987 concentration-dependently increased FMP fluorescence, with an EC 50 value of ϳ30 nM. Consequently, the submaximal concentration of 25 nM of this agonist was chosen to determine the effect of pretreatment with varying concentrations of A-867744. Figure 5a , consistent with the electrophysiological observation, shows that A-867744 failed to increase the signals. In addition, the comparison of the concentration responses to PNU-282987 measured in the presence or absence of 10 M A-867744 revealed overlapping curves (Fig. 5b) . In comparison with A-867744, NS1738 at 30 M was able to potentiate the submaximal ␣7 agonist (25 nM PNU-282987)-evoked responses by 162.2 Ϯ 1.6% (n ϭ 2), illustrating that only certain PAMs are effective. These observations collectively demonstrate that the N-terminal region and extracellular loop M2-3 of the ␣7 nAChR are not obligatory for the positive allosteric modulator effect of A-867744. (Fig. 6) . This supports the notion that A-867744 interacts with a region of the nAChR distinct from the N-terminal domain, which contains the agonist/competitive antagonist binding site.
Effect of A-867744 on Native Rat ␣7 Currents in Hippocampus Brain Slices. Consistent with previous observations (Frazier et al., 1998; McQuiston and Madison, 1999) , rapid application of ACh (3 mM) or choline (10 mM) evoked ␣7-like currents in rat hippocampus CA1 interneurons. The bath application of MLA (10 nM) completely inhibited these currents (data not shown), confirming the involvement of ␣7 nAChRs in the generation of these evoked responses.
To characterize the effect of A-867744 on native ␣7 currents, choline (10 mM in pipette) was puffed onto CA1 interneurons to evoke ␣7 currents and A-867744 (10 M) supplied by bath application. A-867744 increased the peak current amplitude and current density (by ϳ2.0-fold), total charge transfer (ϳ3.4-fold), half-width (ϳ3.3-fold), and current decay tau (ϳ2.5-fold). A-867744, hence, had robust effects on the evoked native ␣7 current kinetics ( Fig. 7; Table 2 ).
The effect of A-867744 was also examined on the time course on the recovery of ␣7 currents using variable interval agonist puff applications (i.e., ratio of P2/P1). As shown in Fig. 7c , without A-867744, ϳ15 s was required for the current to recover completely from desensitization. In the presence of 10 M A-867744, a leftward shift in the recovery time course was observed. For example, at the 5-s interval in the presence of A-867744, ␣7 current recovered by ϳ75%, whereas in the absence of the PAM this value was ϳ40%. This observation demonstrates that A-867744 enhances the rate of the recovery of ␣7 current from desensitization/inhibition.
Potentiation of Inhibitory Synaptic Activity by A-867744 in Dentate Gyrus Granule Cells. ␣7 nAChRs are also present in dentate gyrus in which they are known to regulate GABAergic spontaneous IPSCs recorded in granule cells (Frazier et al., 2003) . In this study, spontaneous IPSCs were also recorded from rat dentate gyrus granule cells, and the effect of A-867744 was determined. A representative experiment from this series of studies is shown in Fig. 8 . The bath application of choline (1 mM) moderately increased the IPSC activity. The application of A-867744 (10 M) that on its own did not have any effect, potentiated the choline evoked spontaneous IPSCs evoked over the range from ϳ5 to 30 pA. This illustrates that A-867744 enhances the choline evoked GABAergic activity in the dentate gyrus.
Discussion
In this study, we describe in vitro properties of A-867744, a novel and selective ␣7 PAM. Similar to PNU-120596 and TQS , A-867744 potentiated AChevoked ␣7 currents in a manner characteristic of type II PAMs (i.e., increasing peak current and strongly affecting the apparent current decay). Although at highest concentrations tested, A-867744, just like TQS and PNU-120596, produced essentially nondecaying agonist-evoked current pro- Table 2 . b, traces from a different cell in which the interpuff interval (current evoked by 10 mM choline in the pipette as indicated by the arrows) was varied (2, 5, or 10 s) in the absence or presence of 10 M A-867744. Each overlapping traces indicate a pair of consecutive responses, with the first (P1) being marked with an asterisk ‫)ء(‬ and the second trace (P2), without ‫,ء‬ obtained after the specified interval. c, summary of the mean values for the P2/P1 ratio obtained for the various interpuff intervals in the presence or absence of 10 M A-867744. A-867744 allows for a faster recovery of the ␣7 current. Each data point is n ϭ 2 to 5. The experiments shown in a to c were carried out at H pot of Ϫ80 mV and in the presence of TTX, atropine, CNQX, APV, and picrotoxin as described under Materials and Methods.
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file, at lower concentrations a qualitative difference was noted. In contrast to TQS and PNU-120596, A-867744 did not evoke a distinct secondary component, suggesting existence of additional types of PAM profiles. The potentiating effect of A-867744 was observed at recombinant human or rat ␣7 expressed in oocytes and native rat ␣7 receptors in the hippocampus (CA1 interneurons) and dentate gyrus. In the presence of A-867744, the responses to ACh were potentiated by increases in the Hill slope, potency, and maximal efficacy. Furthermore, A-867744 accelerated the time course of ␣7 current recovery from desensitization in hippocampus slices, a finding not previously shown for any ␣7 PAM. A-867744 failed to enhance responses at other nicotinic or 5-HT 3A subunits examined, and it did not increase responses mediated by chimeric human ␣7/5-HT 3 receptors, composed of the N terminus and M2-3 loop sequence of human ␣7 and the remainder of human 5-HT 3A . A-867744, similar to PNU-120596, TQS, and NS1738, did not displace the binding of [ 3 H]MLA to ␣7 receptor consistent with the interaction of these compounds with an allosteric site. However, A-867744, unlike these three PAMs, displaced the binding [ 3 H]A-585539 to ␣7 receptors. This displacement did not occur in the ␣7/5-HT 3 chimera, which retains the ligand binding N-terminal domain of the ␣7 receptor, and was activated by ␣7 agonists. Our data show that A-867744 is a novel ␣7 PAM exhibiting a unique pharmacological interaction with the ␣7 nAChR.
In addition to A-867744, several other compounds have been described to function as ␣7 nAChR PAMs: 5-HI, ivermectin, genistein, NS1738, CCMI, galantamine, LY-2087101, PNU-120596, TQS, and SB-206553 (for review, see Lightfoot et al., 2008; Bertrand and Gopalakrishnan, 2007) . Based on the manner by which ␣7 current potentiation occurs, at least two types of PAMs are distinguished. Type I PAMs exhibit a predominant effect on peak current amplitude with little effect on current decay, exemplified by NS1738, 5-HI, and genistein (Zwart et al., 2002; Grønlien et al., 2007; Timmermann et al., 2007) . A-867744 exhibits a different profile similar to that of TQS and PNU-120596 (Hurst et al., 2005; Grønlien et al., 2007) . These compounds, classified as type II PAMs, also increase the peak current amplitude and have a strong effect on the current decay profile. At highest concentrations tested for type II PAMs, the ␣7 agonist-evoked currents are essentially nondecaying.
The effects at lower concentrations tested revealed an important difference between A-867744 and the other type II PAMs under the conditions used in this study (Fig. 1) . Unlike TQS or PNU-120596, A-867744 was not able to activate a distinct secondary component. This suggests that type II PAMs may be further divided. Another property of type II PAMs, including for A-867744 (Fig. 1e ), is that they are able to reactivate desensitized ␣7 nAChRs, unlike type I PAMs (Hurst et al., 2005; Grønlien et al., 2007) . We further provide evidence that the reactivation depends on ␣7 nAChR activity because MLA was able to attenuate the responses to A-867744 in the presence of an ␣7 agonist, NS6784 (Fig. 3) .
A Bertrand et al., 2008) . In the present study, we report a K d value of 0.15 nM in chimera containing an additional ␣7 encoded M2-3 loop, indicating an ϳ5-fold increase in affinity. In addition, A-867744, but not the NS1738, TQS, or PNU-120596, displaced the binding of [ (Fig. 6) . Although the mechanism responsible for the differential profile of A-867744 versus other PAMs remains to be established, we hypothesize that the same allosteric site interaction is involved in the displacement of [ A-867744 was effective in comparably potentiating recombinant human and rat ␣7 nAChRs and also in enhancing agonist evoked native ␣7 currents in rat hippocampus CA1 interneurons. This effect on CA1 interneurons is similar to that reported previously for PNU-120596 (Hurst et al., 2005) . We further quantify that in the presence of A-867744, ␣7 currents in the CA1 hippocampus were enhanced at least 2-fold in amplitude, total charge transfer, half-width, and current decay (Table 2 ). We also show that A-867744 was able to reduce the time course of recovery of ␣7 current from desensitization. Such effect, to our knowledge, has not yet been described for any type II PAM. In the case of type I PAMs, there is a report showing that 5-HI slowed the time course of recovery of ␣7 currents (Zwart et al., 2002) , an opposite effect to that observed in this study for A-867744. Whether this difference is specific for these two PAMs or constitutes a fundamental type I versus II distinction remains to be elucidated. It should also be noted that the process of ␣7 current recovery from desensitization is complex and involves dissociation of ligand from multiple sites and conformational state transitions (Palma et al., 1996; van Hooft and Vijverberg, 1996) . Any given PAM may, hence, affect the on and off rates of the agonist, in addition to its onand off-rate kinetics and the conformational transitions in the basal-open-desensitized triad, including reversal of desensitized receptors favoring the open active state. Both types of ␣7 PAMs have been reported to improve cognitive function or sensory gating deficits (Hurst et al., 2005; Ng et al., 2007; Timmermann et al., 2007) . Likewise, in vivo studies with A-867744 in the DBA/2 mouse model showed significant improvement in sensory gating deficits (Faghih et al., 2009) . Although molecular and cellular mechanisms responsible for these in vivo observations remain to be elucidated, it is likely that effects on synaptic transmission play a role as shown by the responses of 5-HI and PNU-120596 in rat cerebellum and hippocampus (Frazier et al., 2003; Hurst et al., 2005; Thinschmidt et al., 2008) . Similarly in this study, A-867744 enhanced choline evoked spontaneous GABAergic IPSC activity in dentate gyrus.
Both ␣7 nAChRs and 5-HT 3 receptors share substantial homology, which has been used experimentally by swapping homologous domains generating functional chimeric receptors. The earliest reported chimera contained the N-terminal region of chick ␣7 fused to mouse 5-HT 3 (Eiselé et al., 1993) . Other reported chimeras involved the N-terminal region of human ␣7 and the rest of sequence encoded by mouse 5-HT 3 (Craig et al., 2004) , the N-terminal region of rat ␣7 and the remainder being mouse 5-HT 3 (Young et al., 2008) , and the N-terminal sequence of human ␣7 and the remainder of human 5-HT 3A . Additional human ␣7/human 5-HT 3A chimeras were also described previously . One of which contained the N terminus and M2-3 extracellular loop of human ␣7 sequence and the rest human 5-HT 3A . In this study, we show that this chimera is also functional when stably expressed in HEK-293 cells and assessed using patch clamp and membrane potential imaging (Fig. 5) . It is important to note that A-867744 failed to potentiate agonist-evoked chimeric responses whether obtained by submaximal (Fig. 5) or supramaximal (chimeric current expressed in X. laevis oocytes and evoked by 100 M ACh; data not shown) concentrations, indicating that its site of interaction probably involves regions beyond the N-terminal domain and M2-3 extracellular loop. A recent report has provided evidence that PNU-120596 and LY-2087101, type II and I PAMs, respectively, interact within the transmembrane domain at two critical amino acids (Ala225 and Met253) using single-site mutagenesis of chimeric receptors (Young et al., 2008) . Taken together, these studies show that there are multiple binding sites for ␣7 nAChR allosteric potentiators.
In summary, this study identifies a novel and selective type II ␣7 nAChR PAM, A-867744, active at both recombinant and native ␣7 nAChRs that exhibits unique pharmacological interaction with the ␣7 nAChR. Availability of tools such as A-867744 further expands opportunities to elucidate the underlying mechanisms involved in allosteric modulation of the ␣7 nAChR.
